BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE Drug Patent Profile

Which patents cover Bacitracin-neomycin-polymyxin W/ Hydrocortisone Acetate, and when can generic versions of Bacitracin-neomycin-polymyxin W/ Hydrocortisone Acetate launch?

Bacitracin-neomycin-polymyxin W/ Hydrocortisone Acetate is a drug marketed by Altana and Padagis Us and is included in two NDAs.

The generic ingredient in BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is bacitracin zinc; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate. There are twenty-seven drug master file entries for this compound. Additional details are available on the bacitracin zinc; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate profile page.

Summary for BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Altana	BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE	bacitracin; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	060731-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Padagis Us	BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE	bacitracin zinc; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	062166-002	Approved Prior to Jan 1, 1982		RX	No	Yes

Bacitracin-Neomycin-Polymyxin B w/ Hydrocortisone Acetate: Market Landscape and Patent Analysis

Last updated: February 19, 2026

Bacitracin-neomycin-polymyxin B sulfate with hydrocortisone acetate is a multi-component topical ophthalmic and otic preparation. Its primary utility lies in treating superficial bacterial infections of the eye and ear, compounded by inflammatory conditions due to the inclusion of a corticosteroid. The market for such multi-component antibiotic-steroid combinations is influenced by the prevalence of common infections, the development of antibiotic resistance, and the patent protection surrounding specific formulations and delivery methods. This analysis examines the patent landscape and fundamental market drivers for this drug combination.

What is the Market Size and Growth Potential?

The global market for ophthalmic anti-infectives is substantial, driven by conditions like conjunctivitis, keratitis, and blepharitis, which frequently have a bacterial component. The inclusion of a corticosteroid addresses the inflammatory response often accompanying these infections, increasing the product's therapeutic breadth.

• Ophthalmic Anti-infectives Market: The global ophthalmic anti-infectives market was valued at approximately USD 3.1 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 5.2% from 2023 to 2030. This growth is attributed to an increasing incidence of eye infections, rising awareness, and technological advancements in drug delivery systems [1].
• Otic Anti-infectives Market: The otic anti-infectives market, while smaller, also contributes to the overall demand. Ear infections, particularly otitis media and otitis externa, are common, especially in pediatric populations.
• Steroid Component Impact: The hydrocortisone acetate component expands the addressable market to include conditions where inflammation is a significant factor, such as allergic conjunctivitis with secondary infection or inflammatory otic conditions.
• Competition: The market includes a range of single-agent antibiotics, multi-agent antibiotics, and antibiotic-steroid combinations. Generic competition is significant for older, off-patent molecules like bacitracin, neomycin, and polymyxin B.

What is the Intellectual Property Landscape?

The core components of this combination – bacitracin, neomycin sulfate, and polymyxin B sulfate – are older antibiotic classes, and their basic compositions are long out of patent. Hydrocortisone acetate, a corticosteroid, is also a well-established compound with expired patents for its basic chemical entity. Therefore, intellectual property protection for this specific drug formulation primarily centers on:

• Novel Formulations: Patents may cover specific excipients, stabilizers, preservatives, or pH adjusters that enhance the stability, efficacy, or delivery of the combined active pharmaceutical ingredients (APIs). Examples include:
  • Specific emulsion or suspension formulations designed for improved ocular penetration or retention.
  • Preservative-free formulations addressing patient sensitivities.
  • Methods of manufacturing the combined product to ensure API compatibility and stability.
• Delivery Systems: Innovations in dispensing devices or novel delivery methods for topical ophthalmic or otic applications can be patented.
• Specific Indications or Combinations: While the individual components are old, new patents might arise for specific therapeutic uses of the combination in particular patient populations or for distinct disease sub-types, though this is less common for such a foundational therapy.
• Manufacturing Processes: Proprietary methods for synthesizing or purifying the individual APIs or for combining them in a stable and effective manner can be patented.

Example Patent Trends:

Searches of patent databases reveal ongoing patent activity in the ophthalmic and otic drug space. While direct patents for the basic combination of bacitracin, neomycin, polymyxin B, and hydrocortisone are unlikely due to age, patents frequently emerge for:

• Formulation improvements: Enhancements in viscosity, solubility, or sustained release properties.
• Sterile manufacturing techniques: Methods for ensuring sterility in multi-API formulations.
• Combination therapies: While not directly for this exact combination, broader patents may exist for co-formulations of antibiotics and steroids for ocular or otic use.

Due to the age of the active ingredients, the primary barrier to market entry for new manufacturers is typically regulatory approval and cost-effective manufacturing, rather than a lack of patent freedom to operate on the basic API combination. However, specific branded formulations may have patent protection on their unique excipient profiles or manufacturing processes, which can provide a period of market exclusivity.

What are the Key Fundamental Drivers and Challenges?

Market Drivers:

• Prevalence of Bacterial Infections: Common conditions like bacterial conjunctivitis and otitis externa remain significant drivers of demand for topical antibiotic treatments.
• Inflammatory Component: The presence of hydrocortisone acetate addresses the common co-occurrence of inflammation, making it a convenient single-agent therapy for many patients.
• Broad Spectrum of Activity: The combination of bacitracin (Gram-positive), neomycin (Gram-negative), and polymyxin B (Gram-negative) provides coverage against a wide range of common bacterial pathogens.
• Established Efficacy and Safety Profile: These are older, well-characterized drugs with extensive clinical history, offering a degree of predictability for prescribers.
• Cost-Effectiveness (Generic Market): For generic manufacturers, the established nature of the APIs allows for competitive pricing.

Market Challenges:

• Antibiotic Resistance: Growing concerns about antimicrobial resistance (AMR) necessitate judicious use of antibiotics and drive research into novel anti-infective agents. This can lead to a preference for single-agent therapy when pathogen identification is possible, or a shift towards newer classes of antibiotics.
• Allergic Reactions and Sensitization: Neomycin, in particular, is a known sensitizer and can cause allergic contact dermatitis in a subset of patients, potentially limiting its use or necessitating alternative treatments.
• Corticosteroid Side Effects: The use of corticosteroids, even topically, carries risks such as increased intraocular pressure, cataract formation, and delayed wound healing, requiring careful patient selection and monitoring.
• Competition from Newer Agents: Newer antibiotics with improved resistance profiles, enhanced penetration, or reduced side effects are continually entering the market, potentially displacing older combinations.
• Regulatory Scrutiny: Combination products, especially those containing corticosteroids, often face rigorous regulatory review processes.
• Genericization: The lack of patent protection on the core APIs means that the market is highly competitive, with significant price pressure from generic manufacturers.

What is the Competitive Landscape?

The competitive landscape for bacitracin-neomycin-polymyxin B with hydrocortisone acetate is characterized by both branded and generic products.

Branded Products: While specific brand names can change and new entities emerge, historical examples of similar combination ophthalmic preparations include formulations from major pharmaceutical companies that may have held patents on specific delivery systems or proprietary formulations at one time.

Generic Products: A significant portion of the market is served by generic manufacturers who produce the combination in various dosage forms (e.g., ophthalmic suspensions, ointments). Key players in the generic ophthalmic market often include companies such as:

• Teva Pharmaceuticals
• Sandoz (a Novartis company)
• Aurobindo Pharma
• Viatris (formed by the merger of Mylan and Pfizer's Upjohn)
• Allergan (now part of AbbVie) – historically a major player in branded ophthalmics, now also involved in generics through its own portfolio and past divestitures.

Key Competitive Factors:

• Price: In the generic space, price is a dominant factor.
• Availability and Supply Chain Reliability: Consistent supply is crucial for prescribers and patients.
• Formulation Quality: While the APIs are standard, differences in excipients, sterility, and stability can influence product preference.
• Regulatory Approvals: The ability to obtain and maintain FDA (or equivalent) approval is fundamental.

The market for this specific combination is mature, with established players and a strong generic presence. Differentiation for any single manufacturer is likely to come from manufacturing efficiency, supply chain strength, and potentially niche formulation advantages that may have limited patent protection.

What are the Regulatory Considerations?

The regulatory pathway for bacitracin-neomycin-polymyxin B sulfate with hydrocortisone acetate depends on whether a company is seeking approval for a new drug application (NDA) or an abbreviated new drug application (ANDA) for a generic product.

• New Drug Application (NDA): For a novel formulation, new indication, or a completely new drug product incorporating these APIs, a full NDA would be required. This involves extensive pre-clinical and clinical trials to demonstrate safety and efficacy. Given the age of the APIs, a new NDA would likely focus on a novel delivery system, a unique formulation leading to improved outcomes, or a specific, unmet therapeutic need. The time and cost for an NDA are substantial.
• Abbreviated New Drug Application (ANDA): For generic versions of an already approved drug, an ANDA is filed. To be approved, a generic product must demonstrate:
  • Bioequivalence: The generic drug must be shown to be bioequivalent to the reference listed drug (RLD). For topical ophthalmic and otic products, bioequivalence is typically demonstrated through pharmacokinetic studies (if applicable) or often through in vitro testing and comparison of formulation characteristics, along with clinical studies to show equivalent safety and efficacy.
  • Same API: The active pharmaceutical ingredients must be identical to the RLD.
  • Same Dosage Form, Route of Administration, and Strength: These parameters must be consistent.
  • Same Indications for Use: The generic product is approved for the same therapeutic uses as the RLD.
  • Equivalent Labeling: The labeling must be substantially the same as the RLD's approved labeling, with specific allowances for differences related to the manufacturer or excipients.
• FDA Oversight: The U.S. Food and Drug Administration (FDA) regulates ophthalmic and otic drugs. The Center for Drug Evaluation and Research (CDER) reviews these applications.
• Good Manufacturing Practices (GMP): Manufacturers must adhere to strict GMP regulations to ensure product quality, purity, and consistency.
• Preservative Considerations: Formulations may be approved as preservative-containing or preservative-free, with specific regulatory requirements for each. Preservative-free formulations are often preferred for chronic ophthalmic use due to potential toxicity of preservatives to ocular tissues.

The regulatory landscape for this established combination is well-defined, with a clear path for generic approval. The primary hurdles are demonstrating bioequivalence and meeting manufacturing quality standards.

What are the Key Takeaways?

Bacitracin-neomycin-polymyxin B with hydrocortisone acetate is a mature therapeutic product with a stable market. Its intellectual property landscape is dominated by expired patents on the core APIs, with any remaining patent exclusivity likely tied to novel formulations, delivery systems, or manufacturing processes. The market is driven by the prevalence of common bacterial eye and ear infections compounded by inflammation, but faces challenges from antibiotic resistance and competition from newer agents. The regulatory environment is well-established, particularly for generic manufacturers seeking ANDA approval, where bioequivalence and adherence to GMP are paramount. Investment considerations should focus on manufacturing efficiency, supply chain robustment, and understanding the competitive pricing dynamics of the generic market, rather than novel R&D potential in the core API combination.

Frequently Asked Questions

1. Are there any new patents being filed for the basic combination of bacitracin, neomycin, polymyxin B, and hydrocortisone? Patents for the fundamental chemical entities and their basic combination are highly unlikely due to their long-standing presence in medicine. Any new patents would typically pertain to advanced formulations, novel delivery methods, specific manufacturing processes, or unique therapeutic applications not previously established.

2. What are the primary risks associated with developing or investing in a generic version of this drug? Key risks include intense price competition from numerous generic manufacturers, potential regulatory hurdles in demonstrating bioequivalence for topical products, and the ongoing challenge of antibiotic resistance which could lead to decreased physician preference over time.

3. How does the increasing prevalence of antibiotic resistance impact the market for this combination therapy? Antibiotic resistance poses a challenge by potentially reducing the efficacy of older antibiotics like neomycin and polymyxin B. This can lead to a preference for newer, more potent antibiotics or single-agent therapies when specific pathogens are identified, potentially shrinking the market share for broad-spectrum older combinations.

4. What is the typical duration of market exclusivity for a branded formulation of this drug if new intellectual property is secured? If a new patent is granted for a novel formulation or delivery system, market exclusivity could last up to 20 years from the patent filing date, subject to patent term extensions and other regulatory allowances. However, the underlying APIs remain off-patent, meaning generic competition could emerge once the specific formulation patent expires or is successfully challenged.

5. What role do excipients play in the patentability of formulations containing bacitracin-neomycin-polymyxin B with hydrocortisone acetate? Excipients are critical for patentability in this context. Novel excipient combinations, unique ratios, or specific excipients that enhance drug stability, solubility, penetration, or reduce irritation can form the basis of patent claims for a specific formulation.

Citations

[1] Grand View Research. (2023, October). Ophthalmic Anti-infectives Market Size, Share & Trends Analysis Report By Drug Class (Antibiotics, Antivirals, Antifungals), By Indication (Bacterial Infections, Viral Infections, Fungal Infections), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/ophthalmic-anti-infectives-market